From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Baseline | 12 months | 30 months | |||
---|---|---|---|---|---|---|
 | Total cohort | NOMID/ CINCA | Total cohort | NOMID/ CINCA | Total cohort | NOMID/ CINCA |
Number of patients, N | 91 | 14 | 67 | 8 | 28 | 4 |
Number (%) of patients in disease remission (physician assessment) | 61 (68.5) | 11 (78.6) | 42 (66.7) | 4 (66.7) | 19 (67.9) | 4 (100.0) |
Physician Global Assessment, percentage of absent/mild-moderate/severe rating, % | 40 / 53 / 2 | 57 / 36 / 0 | 33 / 60 / 2 | 33 / 50 / 0 | 61 / 39 / 0 | 75 / 25 / 0 |
Patient assessment of current disease activity; 0–10, median (min; max) | 2.0 (0; 7) | 1.0 (0; 6) | 1.0 (0; 7) | 1.0 (0; 5) | 0.0 (0; 7) | 0.0 (0; 4) |
Patient assessment of current fatigue; 0–10, median (min; max) | 3.0 (0; 9) | 2.0 (0; 6) | 3.0 (0; 8) | 2.0 (0; 8) | 1.0 (0; 8) | 4.0 (0; 5) |
Number (%) of patients without impairment of social life by the disease | 32 (52.5) | 4 (50.0) | 31 (62.0) | 3 (42.9) | 11 (47.8) | 1 (33.3) |
CRP/SAA, median (mg/dl) | 0.1/0.3 | 0.2/0.4 | 0.1/0.5 | 0.5/0.9 | 0.0/0.3 | 0.2/0.1 |